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Analysis of degree and rate of healing was performed based
on initial wound size.
Results:The study included142LEBand148EVpatients
with similar age (EV 70, LEB 71), diabetes mellitus (EV 58%,
LEB 41%), and chronic renal failure (EV 24%, LEB 21%). EV
procedures (balloon angioplasty n 20, stent deployment n
82, atherectomy n  30, and cryoplasty n  10) treated SFA
(30%), popliteal (19%), and tibial (51%) lesions with 2.8 lesions
treated per patient. LEB included 98 vein grafts and 44 using
PTFE with a distal vein patch. Target arteries included BK pop-
liteal (n 14), anterior tibial (n 46), posterior tibial (n 41),
and peroneal (n 41). Therewas no difference in average initial
wound size (EV14.1mm,LEB14.6mm)with complete healing
in 76% after LEB and 41% after EV (p 0.013). This difference
was significant in larger wounds (Group C) with complete heal-
ing in 70%LEB and 27%EV (p 0.02). A shortermedian time
to healing was noted after bypass; LEB 98 days, EV 132 days
(p 0.048). There were 40 amputations; EV 30 (20% total, 8%
major), and LEB 10 (7% total, 2.8%major).
Conclusions: This comparison of wound healing after
bypass or endovascular revascularization demonstrates
more complete healing and a faster rate of healing after
open bypass for larger wounds ( 2 cm). Initial wound size
should be a consideration in choosing the method of
revascularization for ischemic wounds.
Healing based on initial wound size
Group LEB EV
A (0-5 mm) 81.1% 94 days 53.8% 105 days
B (5.1 – 20 mm) 76.2% 102 days 41.7% 128 days
C ( 20 mm) * 70.2% 115 days 27.1% 164 days
*p  0.01
Author Disclosures: C. E. Attinger: Nothing to disclose;
J. Babrowicz: Nothing to disclose; D. Deaton: Nothing
to disclose; J. Laredo: Nothing to disclose; R. F. Neville:
WL Gore, Honorarium; J. Steinberg: Nothing to disclose.
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Video Presentation
Popliteal to Dorsalis Pedis Translocated Vein Graft
Frank W. LoGerfo1, Frank B. Pomposelli1, Allen Hamdan1,
Bernadette Aulivola2. 1Beth Israel Deaconess Medical Center,
Boston,MA; 2Loyola UniversityMedical center, Chicago, IL
Background: Autogenous vein bypass grafts to the dor-
salis pedis artery are an essential surgical skill in the care of
patients with foot ulcers associated with Diabetes Mellitus.
Technical Description: This is a video showing the key
steps in the performance of a popliteal to dorsalis pedis translo-
cated vein graft demonstrating angioscopically verified valve lysis.
Author Disclosures: B. Aulivola: Nothing to disclose; A.
Hamdan: Nothing to disclose; F. W. LoGerfo: Nothing
to disclose; F. B. Pomposelli: Nothing to disclose.SS17.
Vacuum-Assisted Closure (VAC) Therapy for the Treat-
ment of Deep (Szilagyi Grade III-Infection) in the Groin
Ramesh Tripathi1, Kiriakos Ktenidis2. 1Vascular & Endo-
vascular Surgery, Indraprastha Apollo Hospital, New
Delhi, Hungary; 2Aristotle University, Thessaloniki, Greece
Objectives: To evaluate the benefit of vacuum-assisted
closure (VAC) therapy for the treatment of deep alloplastic
graft infections (Szilagyi Grade III-Infection) in the groin.
Methods: From 2000 to 2009, 72 deep inguinal infec-
tions involving native as well as synthetic graft or patch
material. There were 29 early graft infections ( 30 days
after implantation) and 43 late infections. 55 cases involved
non-native grafts/patches (26 PTFE grafts, 24 Dacron
grafts, 5 Vascuguard Bovine Pericardial patches). All pa-
tients were treated with multiple wound debridements,
graft salvage, sartorius myoplasty, IV antibiotics and VAC
dressings till thru-surface healing was achieved. Exclusion
criteria were an alloplastic graft infection with proximal
expansion above the inguinal ligament, blood culture pos-
itive septicaemia or septic anastomotic herald or overt
bleeding.
Results: At 9 months, overall, graft/patch salvage was
achieved in 70/72 (97.2%) patients. In the non-native
group, vein or synthetic graft preservation without revision
was achieved in 48/55 (82.27%) patients. The mean dura-
tion of VAC treatment was 16  7.7 days, postoperative
mean hospital stay was 25.3 8.5 days. In 23 (31.9%) cases
a secondary closure of the wound could be achieved. In 49
cases wound healing was achieved by meshed split skin
grafting. Mean wound healing time for all wounds was
24.3 12.5 days. Mean postoperative follow-up was 4.3
3.5 years with no procedure-related mortality. Specific
complications during VAC-therapy were wound fluid re-
tention in 2 cases and an increased need for analgesics in 12
patients.
Conclusions: Even in the presence of synthetic vascu-
lar graft material, negative pressure therapy can greatly
simplify challenging wound-healing problems. Our long-
term experience demonstrates the safety and effectiveness
of VAC-therapy for the treatment of deep graft infections.
Author Disclosures: K. Ktenidis: Nothing to disclose; R.
Tripathi: Nothing to disclose.
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Low Rehospitalization Rate for Vascular Surgery Pa-
tients at a Single University Hospital
Benjamin M. Jackson1, Lynne Doctor2, Derek Nathan3,
Grace J. Wang1, Edward Y. Woo1, Ronald M. Fairman1.
1Hospital of the Univeristy of Pennsylvania - Division of
Vascular Surgery, Philadelphia, PA; 2University of Pennsyl-
vania School ofMedicine, Philadelphia, PA; 3General Surgery,
Hospital of the University of Pennsylvania, Philadelphia, PA
Objectives: Reducing rehospitalization rates has been
proposed to improve care, reduce costs, and as a pay-for-
performance criterion. Recent review of Medicare claims
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Volume 51, Number 11S Abstracts 13Sdata indicates that vascular surgery patients have among the
highest rates of 30-day readmission at 23.9%.
Methods: We retrospectively examined all patients dis-
charged from the vascular surgery service at a single university
hospital over 12 months. We also prospectively followed pa-
tients discharged over one month. 2 tests with Bonferroni
correction were used.
Results: 96 (13%) of the 766 patients discharged
from vascular surgery were readmitted within 30 days.
Of the readmissions, 72 (75%) were unplanned; there-
fore, the unplanned readmission rate was 9%. The most
frequent reasons for unplanned readmission were wound
complications (29%), worsening peripheral arterial dis-
ease (PAD) or nonhealing ulcers (23%), electrolyte dis-
turbance/emergent dialysis (8%), and graft occlusion
(6%). One patient died during readmission. In the pro-
spective study, 13% of patients were readmitted; none
were readmitted to an outside hospital. The presence of
diabetes predicted readmission (p  0.001). Patients
undergoing procedures for PAD (12%) and end stage
renal disease (ESRD) (12%) had a higher (p  .03)
readmission rate than those undergoing procedures for
abdominal aortic aneurysm (4%) or carotid stenosis (4%).
Conclusions: Rehospitalization in vascular surgery pa-
tients can be reduced below rates gleaned from interrogation
of Medicare data. Diabetics and patients undergoing proce-
dures for PAD or ESRD are more likely to be readmitted.
Freedom from readmission in vascular surgery patients
Author Disclosures: L. Doctor: Nothing to disclose; R. M.
Fairman: Nothing to disclose; B. M. Jackson: Nothing to
disclose;D. Nathan: Nothing to disclose;G. J. Wang: Noth-
ing to disclose; E. Y. Woo: Nothing to disclose.
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Differential Expression of ERK and Akt Following Nitric
Oxide Exposure in Type 1 and Type 2 Diabetic Rats
Zachary Emond, Vinit Varu, Sadaf Ahanchi, Janet Mar-
tinez, Melina R. Kibbe. Vascular Surgery, Northwestern
University, Chicago, ILObjectives: Diabetic patients develop greater reste-
nosis from neointimal hyperplasia after vascular interven-
tions. Previously, we reported that nitric oxide (NO)
decreased neointimal hyperplasia significantly more in
type 2 diabetic rats than controls, but not at all in type 1
diabetic rats. Given the different insulin levels between
these animal models, and that insulin is known to regu-
late ERK and Akt, we hypothesized that NO differen-
tially effects ERK and Akt activity in type 1 vs type 2
diabetic rats.
Methods: To induce type 2 diabetes, Zucker diabetic
fatty (ZDF) rats were fed Purina 5008 chow. To induce type
1 diabetes, lean Zucker (LZ) rats were injected with strepto-
zotocin (STZ; 60mg/kg). Rats with glucose300mg/dL
were included in the study. Non-STZ LZ rats served as
controls. The carotid artery injury model was performed.
Groups included injury and injuryPROLI/NO (20 mg)
[n6/group].At 14days, phosphorylatedERK(pERK) and
Akt (pAkt) expression was assessed by immunofluorescent
staining.
Results: There were no changes in pERK expression
after NO treatment in LZ control and type 1 diabetic rats
but increased expression in type 2 diabetic rats (44%, p 
0.009). This increase was observedmainly in the adventitia.
pAkt expression decreased in the LZ control (47%, p 
0.012) and type 1 diabetic (51%, p  0.043) rats after NO
treatment but increased in type 2 diabetic rats (53%, p 
0.003). These changes occurred mostly in the neointimal
and adventitia. Interestingly, NO increased the pERK/
pAkt ratio by 29% in the LZ control and 47% in the type 1
diabetic rats but decreased the pERK/pAKT ratio by 12%
in the type 2 diabetic rats.
Conclusions: NO differentially effects the expression
of pERK and pAkt in type 1 vs type 2 diabetic rats, by
decreasing the pERK/pAkt ratio in type 2 diabetic but
increasing this ratio in type 1 diabetic and control rats.
These data suggest one mechanism by which NO inhibits
neointimal hyperplasia in hyperinsulinemic environ-
ments.
Author Disclosures: S. Ahanchi: Nothing to disclose; Z.
Emond: Nothing to disclose; M. R. Kibbe: Nothing to
disclose; J. Martinez: Nothing to disclose; V. Varu: Noth-
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Renal Volume and Blood Pressure Response to Renal
Artery Stenting
J. Gregory Modrall, R. James Valentine, Carlos H. Tima-
ran, Eric B. Rosero, Thomas Anthony, G. Patrick Clagett,
Clayton Trimmer. Surgery, University of Texas Southwest-
ern Medical Center, Dallas, TX
Objectives: The ASTRAL Trial disputed the benefit of
renal artery stenting (RAS) when applied to all hypertensive
patients with renal artery stenoses. However, some patients
may benefit from RAS, and the challenge is to uncover
